Letter

The PROGRESS trial three years later: HOPE trial may shed some light

BMJ 2004; 329 doi: 10.1136/bmj.329.7479.1403-d (Published 9 December 2004)
Cite this as: BMJ 2004;329:1403.5

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. John Attia (John.Attia@newcastle.edu.au), associate professor, epidemiology,
  2. Catherine D'Este, associate professor biostatistics,
  3. Christopher R Levi, conjoint senior lecturer
  1. Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, NSW 2300, Australia
  2. Centre for Clinical Epidemiology and Biostatistics, University of Newcastle, Newcastle, NSW 2300, Australia

    EDITOR—Wennberg and Zimmermann are correct in pointing out that it is simplistic, and potentially misleading, to interpret PROGRESS as indicating that patients with stroke benefit from the combination of perindopril and indapamide.1 In applying these results clinically, doctors need to know whether the benefit in stroke reduction is due mainly to indapamide or to some synergistic effect of the two. After all, given the prevalence …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular